GlassScriptPhysician profile
William G Tanner
NPI 1114911294
$8,354.84
in general payments reported to CMS, 2019-2025
39 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2020: $806 · 2021: $1,430 · 2022: $1,496 · 2023: $1,333 · 2024: $1,267 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,811.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,087.44 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $895.82 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $826.62 | 2019-2025 | Livdelzi |
| Genzyme Corporation | $433.82 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $419.28 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $400.67 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $323.23 | 2019-2025 | |
| Celgene Corporation | $308.22 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $264.11 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $258.31 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $216.31 | 2021-2025 | Ocaliva |
| Lilly USA, LLC | $182.88 | 2024-2025 | Omvoh, Zepbound |
| Braintree Laboratories, INC. | $146.89 | 2019-2024 | Sutab, Suflave |
| Ipsen Biopharmaceuticals, INC | $146.57 | 2024-2025 | Iqirvo, Bylvay |
| Ferring Pharmaceuticals INC. | $144.95 | 2019-2023 | Rebyota |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $138.67 | 2020-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $131.65 | 2019-2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $129.59 | 2020-2022 | |
| Amgen INC. | $124.19 | 2021-2025 | Amjevita, Avsola |
| Ardelyx, INC. | $100.29 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $99.13 | 2025 | Rezdiffra |
| Ucb, INC. | $63.87 | 2019-2020 | |
| Organon LLC | $63.10 | 2023-2024 | Renflexis, Hadlima |
| Aimmune Therapeutics, INC. | $54.15 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $52.74 | 2024-2025 | Vegzelma |
| Redhill Biopharma INC. | $38.20 | 2020-2021 | |
| Intra-Sana Laboratories | $33.30 | 2021-2022 | |
| Boston Scientific Corporation | $33.26 | 2021-2022 | |
| Micro-Tech Endoscopy USA, INC. | $32.83 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $32.73 | 2025 | Voquezna |
| Fresenius Kabi USA, LLC | $30.54 | 2023 | Idacio |
| Alnylam Pharmaceuticals INC. | $25.82 | 2022 | |
| Mylan Institutional INC. | $24.83 | 2023 | Hulio |
| Olympus America INC. | $19.48 | 2019 | |
| Medtronic, INC. | $17.06 | 2025 | Pillcam |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.21 | 2024 | Cyltezo |
| Shionogi INC | $13.11 | 2019 | |
| Concordia Pharmaceuticals INC. | $12.71 | 2019 | |
| Alfasigma USA, INC. | $12.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.